Wolfe Laboratories Addresses Rapid Growth with Executive Appointment
Business Wire: June 14, 2016 – WOBURN, MA, U.S.A. – Wolfe Laboratories today announced that Frank Tagliaferri, PhD, has been appointed vice president, pharmaceutical development, effective immediately. Dr. Tagliaferri will lead technical operations for Wolfe’s rapidly growing client base, bringing a wealth of experience in analytical methodologies, formulation and process development, scaleup, and regulatory functions across highly diverse therapeutic modalities, including small molecules, peptides, proteins, and nucleic acid therapeutics. Dr. Tagliaferri will serve as a member of Wolfe’s executive leadership team and will report to Janet Wolfe, the company’s president and chief executive officer.
“Frank’s proven track record of success in developing and commercializing a broad range of novel therapeutics and dosage forms is essential to Wolfe Laboratories as we grow to meet increased client demand for a strong pharmaceutical development CRO partner,” said Dr. Janet Wolfe. “I am thrilled to have the opportunity to work with Frank; he brings outstanding strategic leadership and technical acumen that will greatly benefit our clients’ programs and overall company growth.”
Most recently, Dr. Tagliaferri co-founded and served as vice president of R&D at 4P Therapeutics with a focus on the design, characterization, and commercial development of novel delivery systems and drug/device combination products for biologics and other complex molecules. Prior to joining 4P Therapeutics in 2012, Dr. Tagliaferri served as vice president of R&D for Altea Therapeutics, where he contributed to the development of the PassPort® system for the transdermal delivery of small molecules and biologics. Dr. Tagliaferri began his career at GeneMedicine (later Valentis, Inc.) where, as director of drug delivery, his focus was on the development and characterization of delivery systems for both DNA and proteins. He later served the same role at Tapestry Pharmaceuticals, working on small molecule anticancer agents and novel RNA-based therapeutics.
“Wolfe Laboratories’ integrated pharmaceutical development services are making a meaningful difference for advancing pipelines at its clients’ companies,” said Dr. Frank Tagliaferri. “I’m excited to join an outstanding team and help Wolfe Laboratories leverage its sophisticated development expertise.”
Dr. Tagliaferri earned his PhD in chemistry from the University of Virginia and a BA in chemistry from Franklin and Marshall College. He was a postdoctoral fellow at the University of Tennessee.
